Cas 1022151-32-1,6-bromo-5-fluorobenzo[d]thiazol-2-amine

1022151-32-1

Post Buying Request

Basic information

Product Name: 6-bromo-5-fluorobenzo[d]thiazol-2-amine
Synonyms:
CAS NO:1022151-32-1
Molecular Formula:
Molecular Weight: 247.091
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 6-bromo-5-fluorobenzo[d]thiazol-2-amine(CAS DataBase Reference)
NIST Chemistry Reference: 6-bromo-5-fluorobenzo[d]thiazol-2-amine(1022151-32-1)
EPA Substance Registry System: 6-bromo-5-fluorobenzo[d]thiazol-2-amine(1022151-32-1)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1022151-32-1(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1022151-32-1 Suppliers

Recommended suppliers

1022151-32-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1022151-32-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,2,1,5 and 1 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1022151-32:
(9*1)+(8*0)+(7*2)+(6*2)+(5*1)+(4*5)+(3*1)+(2*3)+(1*2)=71
71 % 10 = 1
So 1022151-32-1 is a valid CAS Registry Number.

1022151-32-1Upstream product

1022151-32-1Downstream Products

1022151-32-1Relevant academic research and scientific papers

1,6-NAPHTHYRIDINE COMPOUNDS AND METHODS FOR CSK MODULATION AND INDICATIONS THEREFOR

-

Paragraph 0321, (2021/10/11)

Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein R1, R2, R3, R4, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF

-

Page/Page column 51-52, (2018/12/13)

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

-

Paragraph 00822, (2017/01/09)

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS

-

Page/Page column 80, (2008/12/05)

The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1022151-32-1